West Pharmaceutical (WST)

• Market cap: $15.3B
• 1 day: 3.56%
• 5 days: 4.07%
• 1 month: -38.81%
• 3 months: -34.27%
• 6 months: -30.69%
• Year to date: -35.77%
• 1 year: -40.79%
• 5 years: 23.95%
• 10 years: 289.56%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: West Pharmaceutical Services is based in Pennsylvania, U.S., and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

Employees: 10,600

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

150% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 10 (+6) [Q4]

16% more first-time investments, than exits

New positions opened: 94 | Existing positions closed: 81

11% more capital invested

Capital invested by funds: $20.6B [Q3] → $22.8B (+$2.2B) [Q4]

11% more repeat investments, than reductions

Existing positions increased: 279 | Existing positions reduced: 252

1.21% more ownership

Funds ownership: 94.77% [Q3] → 95.97% (+1.21%) [Q4]

2% less funds holding

Funds holding: 721 [Q3] → 707 (-14) [Q4]

44% less call options, than puts

Call options by funds: $77.4M | Put options by funds: $139M

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $325 54% upside
• Avg. target: $368 74% upside
• High target: $400 90% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Keybanc Paul Knight 33% 1-year accuracy 3 / 9 met price target	54% upside $325	Overweight Maintained	14 Feb 2025
Citigroup Thomas Palmer 30% 1-year accuracy 10 / 33 met price target	90% upside $400	Buy Initiated	8 Jan 2025
B of A Securities Derik De Bruin 45% 1-year accuracy 9 / 20 met price target	68% upside $355	Buy Maintained	13 Dec 2024
UBS John Sourbeer 20% 1-year accuracy 1 / 5 met price target	85% upside $390	Buy Upgraded	12 Dec 2024